Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21633992 | 0.89 | GSTP1 (0.46) | DAOGSTP1SORT1SMN1; SMN2HTR2C | |
| SCHEMBL6898539 | 0.89 | FNTA (0.39) | DAOGSTP1SMN1; SMN2HTR2CFNTA | |
| SCHEMBL6895221 | 0.87 | FNTA (0.35) | DAOGSTP1SMN1; SMN2HTR2CFNTA | |
| SCHEMBL6902554 | 0.82 | GSTP1 (0.32) | GSTP1CYP1A2 | |
| SCHEMBL6902367 | 0.79 | PTPN1 (0.34) | DAOGSTP1SORT1CYP1A2 | |
| SCHEMBL1044406 | 0.77 | — | — | |
| SCHEMBL31436467 | 0.77 | FNTA (0.40) | GSTP1FNTAPGGT1B | |
| SCHEMBL31485230 | 0.75 | GSTP1 (0.42) | GSTP1SMN1; SMN2FNTAPGGT1B | |
| SCHEMBL1150883 | 0.73 | ACHE (0.36) | DAOGSTP1 | |
| SCHEMBL28163589 | 0.73 | DHODH (0.33) | SMN1; SMN2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3109309-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3109309-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3109308-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3109308-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3901129-A1 | METHOD FOR SYNTHESISING NOVEL 3-HYDROXY-CYCLOPENTYL ACETIC ACID DERIVATIVE COMPOUNDS | L'OREAL (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-10995051-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cylopentyl acetic acid | L'OREAL (FR) | 2021-05-04 | — | — | US | disclosed |
| EP-3109307-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3109307-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10654788-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cyclopentyl acetic acid | L'OREAL (FR) | 2020-05-19 | — | — | US | disclosed |
| US-20200131108-A1 | METHOD FOR SYNTHESIZING NOVEL COMPOUNDS DERIVED FROM 3-HYDROXY-CYLOPENTYL ACETIC ACID | L'OREAL (FR) | 2020-04-30 | — | — | US | disclosed |
| WO-2013109798-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013109798-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2013-07-25 | — | — | WO | disclosed |
| US-8378147-B2 | Process for producing a 2-alkyl-2-cycloalkene-1-one | KAO CORPORATION (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110040127-A1 | PROCESS FOR PRODUCING A 2-ALKYL-2-CYCLOALKEN-1-ONE | KAO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| EP-2269971-A1 | PROCESS FOR PRODUCING A 2-ALKYL-2-CYCLOALKENE-1-ONE | Kao Corporation (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-6833481-B2 | Catalytic dehydrative isomerization | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1316541-A1 | Process for producing 2-alkyl-2-cyclopentenones | Takasago International Corporation (JP) | 2003-06-04 | — | — | EP | disclosed |
| CN-1421429-A | Process for producing 2-alkyl-2-cyclopentenone | TAKASAGO PERFUMERY CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
| US-4329508-A | Process for making alkyl cyclopentenones | SCM CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654788-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cyclopentyl acetic acid | HSD17B12, FASN, AKR1C3 | DAO 273/4885GSTP1 2982/4885SORT1 4254/4885 |
| US-20110040127-A1 | PROCESS FOR PRODUCING A 2-ALKYL-2-CYCLOALKEN-1-ONE | CYP1B1, GRK1, CYP2J2 | DAO 2077/4885GSTP1 1616/4885SORT1 4857/4885 |
| US-10995051-B2 | Method for synthesizing novel compounds derived from 3-hydroxy-cylopentyl acetic acid | CYP8B1, HAAO, HSD17B12 | DAO 395/4885GSTP1 3431/4885SORT1 3612/4885 |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | HSD3B2, DHPS, HSD3B1 | DAO 2558/4885GSTP1 2717/4885SORT1 4804/4885 |
| US-20200131108-A1 | METHOD FOR SYNTHESIZING NOVEL COMPOUNDS DERIVED FROM 3-HYDROXY-CYLOPENTYL ACETIC ACID | CYP8B1, HAAO, HSD17B12 | DAO 395/4885GSTP1 3431/4885SORT1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.